Ejung Moon is a Group Leader in Radiation Biology and the Tumour Microenvironment at the Department of Oncology, University of Oxford's Medical Sciences Division. Her research focuses on hypoxia-driven tumor progression and radiation response mechanisms. Education: PhD in Pharmacology and Cancer Biology from Duke University Training: Postdoctoral work with Amato Giaccia at Stanford University Research Interests: Elucidating how hypoxia-induced MAFF protein regulates tumor cell invasion, metastasis, and radiation resistance through antioxidant response pathways. Current work explores MAFF dimerization dynamics and metabolic reprogramming in hypoxic tumors. Scientific Contributions: Identified MAFF's role in radiation-induced antioxidant gene regulation (2021, Nature Communications ). Recent studies investigate iron metabolism's impact on FLASH radiotherapy effects. Scientific Awards: Breast Cancer Research Program (BCRP) predoctoral fellowship Laboratory & Collaborations: Moon Lab collaborates with Oxford Cancer and NHS Cancer and Haematology Centre. Key partnerships include Stanford University's radiobiology research groups.
Joshua D. Angrist is the Ford Professor of Economics at the Massachusetts Institute of Technology, where he has been a faculty member since 1996. He is also a co-founder and director of MIT's Blueprint Labs and a Research Associate at the National Bureau of Economic Research. Angrist shares the 2021 Nobel Prize in Economic Sciences with David Card and Guido Imbens for their methodological contributions to the analysis of causal relationships. Angrist received his B.A. from Oberlin College in 1982 and completed his Ph.D. in Economics at Princeton University in 1989. Prior to joining MIT, he taught at Harvard University and the Hebrew University of Jerusalem. His academic journey began somewhat unconventionally, as he left high school early after 11th grade, worked for over a year, and only later discovered his passion for economics through an inspiring teacher at Oberlin. Angrist's research focuses on developing and applying innovative econometric methods to answer important economic questions using natural experiments. His work spans labor economics, education economics, and causal inference methodology. He is particularly known for his contributions to instrumental variables methods and the Local Average Treatment Effect (LATE) framework developed with Guido Imbens. His research explores the economics of education and school reform, the impact of social programs on labor markets, and the effects of immigration and regulation. His recent publications reveal a continued focus on causal inference methods applied to education policy questions, labor market issues, and health economics. The trend shows increasing sophistication in research design, with particular attention to addressing selection bias and developing methods for external validity. His work spans theoretical econometric contributions alongside empirical applications in education, labor markets, and health. Sveriges Riksbank Prize in Economic Sciences in Memory of Alfred Nobel (2021) Fama Prize for Graduate Education (2018) Fellow of the American Academy of Arts and Sciences Fellow of the Econometric Society Angrist is deeply committed to teaching and mentoring. He has developed influential econometrics textbooks including 'Mostly Harmless Econometrics' and 'Mastering Metrics' with Jörn-Steffen Pischke. At MIT, he teaches courses including Labor Economics I (14.661), Econometric Data Science (14.32), and Labor Economics and Public Policy (14.64). He emphasizes selecting UROP students who have mastered foundational economics through courses like 14.64 and 14.32. Beyond MIT, Angrist co-founded Avela, a software startup using cutting-edge research to help schools improve enrollment and operations. Angrist co-founded and directs MIT's Blueprint Labs, which brings together researchers from economics, computer science, and education to develop innovative solutions for educational challenges. Through Blueprint Labs and Avela, his work bridges academic research with practical applications in education policy and technology.
Pascal Frossard is a Full Professor at the Department of Electrical Engineering in the School of Engineering (STI) at EPFL, with a courtesy appointment in the School of Computer and Communication Sciences. He founded and directs the LTS4 laboratory since 2003, co-leads the EPFL AI Center and Swiss Data Science Center, and serves as Associate Dean for Research at STI. Research Focus: Machine Learning, Graph Signal Processing, AI Applications in Healthcare, Computer Vision Academic Leadership: IEEE Fellow, ELLIS Fellow, Conference Chair roles Key Projects: Digital Pathology for Oncology, Cardiac Digital Twins, Robust Machine Learning Research Interests: His work bridges signal processing, machine learning, and applied mathematics, emphasizing biomedical applications. Recent research includes adversarial robustness in classifiers, network representation learning, and 360-degree video analysis. Scientific Awards: IEEE Fellow ELLIS Fellow Leadership in IEEE technical committees Advising & Grants: Supervised 20+ PhD students and postdocs. Secured major grants from PHRT, Hasler Foundation, FNS-Sinergia, Armasuisse, Google, and Cisco.
Romain Lopez is an Assistant Professor of Computer Science and Biology at New York University, with a joint appointment in the Courant Institute of Mathematical Sciences and the Department of Biology. He will be joining NYU in September 2025, bringing expertise at the intersection of machine learning and computational biology. Prior to joining NYU, he was a Postdoctoral Fellow at Genentech and Stanford Medicine from 2021 to 2025, working with Jonathan Pritchard and Aviv Regev. Dr. Lopez received his educational training at prestigious institutions: PhD in Computer Science (2021) from the University of California, Berkeley, advised by Mike Jordan and Nir Yosef M.S. in Applied Mathematics (2016) from École polytechnique, Palaiseau, France Dr. Lopez's research focuses on developing machine learning methods to understand biological systems at the cellular level. His work bridges computational techniques with biological applications, particularly in single-cell and spatial omics analysis. He pioneered probabilistic approaches for single-cell analysis with scVI and co-developed scvi-tools, now widely adopted tools in the field. His research spans deep generative models, causal inference, perturbation modeling, and representation learning for biological data. His publication record demonstrates a consistent trajectory of innovation in computational biology, with recent work focusing on spatial biology, disentangled representations of cellular perturbations, and causal modeling of cellular responses. He has made significant contributions to the field of single-cell analysis, developing methods that help scientists interpret complex cellular data and predict how cells respond to various perturbations. Dr. Lopez has received numerous honors and awards for his research: Best Paper Award from the ICML Workshop on AI for Science (2024) Best Paper Award Honorable Mention from the AAAI Conference on Artificial Intelligence (2021) Best Student Poster Award from the ICML Workshop on Computational Biology (2019) UC Berkeley EECS Departmental Graduate Fellowship (2016) Carnot Foundation Fellowship (2016) Monahan Foundation Fellowship (2016) French National Defence Medal, Bronze Echelon (2014) At NYU, Dr. Lopez will lead the Biological Machine Learning group, which develops probabilistic machine learning methods to uncover biological mechanisms governing cellular behavior and disease. His lab focuses on creating tools that transform complex cellular data into biological insights, with applications in understanding cancer, immune responses, and fundamental cellular processes. His work has significant implications for precision medicine and drug discovery.
Thomas Walz, PhD, is a Professor at The Rockefeller University and Head of the Laboratory of Molecular Electron Microscopy. Previously, he held positions as Assistant, Associate, and Professor at Harvard Medical School (1999–2015) and was an Investigator at the Howard Hughes Medical Institute (2008–2015). He earned his PhD and BS in biophysics from the University of Basel, Switzerland, and completed postdoctoral research at the University of Sheffield. Walz completed his education at the Biozentrum, University of Basel, Switzerland, where he received his Diploma in Biophysics (1992) and PhD in Biophysics (1996). He furthered his training as a postdoctoral researcher at the University of Sheffield (1996–1999). His research focuses on understanding membrane-related processes and the structural biology of membrane proteins in lipid environments. Utilizing cryo-electron microscopy and nanodisc technology, he investigates how lipid bilayers influence membrane protein structure and function. Key areas include mechanosensitive channels, T-cell receptor dynamics, and telomere maintenance mechanisms. Collaborations with the de Lange lab explore the CST-Polα/primase complex's role in telomere regulation. Walz has been recognized with the Genzyme Award for Outstanding Achievement in Biomedical Sciences (2004) and continues to contribute to advancements in structural biology and membrane protein research. While specific student advisees are not listed, Walz actively mentors through his roles in the David Rockefeller Graduate Program and Tri-Institutional programs. His research is supported by grants and institutional funding, though specific grants are not detailed here. He directs the Laboratory of Molecular Electron Microscopy at Rockefeller, a hub for innovative structural biology and membrane protein studies. The lab collaborates widely, integrating cryo-EM with electrophysiology and molecular dynamics simulations.
Jonas Fischer is the head of the Explainable Machine Learning group at the Max Planck Institute for Informatics, Department of Computer Vision and Machine Learning. His research focuses on interpreting complex machine learning models, particularly in genomics and healthcare, aiming to enhance robustness and alignment with human decision-making. Prior to his role at MPI, he was a postdoctoral fellow at Harvard University's Department of Biostatistics, where he worked on interpretable models for gene regulatory systems in cancer. Education: PhD in Computer Science from Saarland University (2022), with a thesis titled More than the sum of its parts , exploring the intersection of pattern mining and deep learning. He has contributed to advancing methods in neural network pruning, federated learning, and low-dimensional embeddings (e.g., dtSNE, Mercat). His work bridges computational biology, data mining, and machine learning, with applications in DNA methylation analysis, graph-based differential networks, and biomedical informatics. Key research areas include: (1) Explainable AI and neural network interpretability, (2) Biomedical applications of machine learning (e.g., gene regulatory networks, cancer genomics), (3) Low-dimensional embeddings and visualization techniques, (4) Federated learning for privacy-preserving collaborative models, and (5) Pattern mining for error analysis in NLP and classification tasks. Publications span top venues like NeurIPS, ICLR, Bioinformatics, and Genome Biology. His group develops tools such as BONOBO for omics data integration and node2vec2rank for scalable graph analysis. He actively collaborates with biomedical researchers to address challenges in data-driven healthcare and precision medicine.
Dr. Jimeng Sun is a Health Innovation Professor at the Siebel School of Computing and Data Science and Carle Illinois College of Medicine at the University of Illinois Urbana-Champaign. Co-founder of Keiji AI , he leads groundbreaking research at the intersection of artificial intelligence and healthcare, actively deploying clinical AI systems and developing frameworks like PyHealth and Therapeutics Data Commons . His research spans four major areas: Clinical AI Systems : Developing interpretable models (e.g., RETAIN) for patient similarity, temporal event prediction, medication recommendation, and clinical outcome forecasting Drug Discovery : Creating molecular optimization frameworks, drug-target interaction models, and AI-driven platforms Clinical Trials : Pioneering patient-trial matching, outcome prediction, and optimization frameworks using deep learning and graph neural networks Biosignal Analysis : Advancing sleep staging, seizure classification, and automated EEG/Cardiac monitoring systems With over 500 top-tier publications (including in Nature , NEJM AI , and leading AI conferences) and an h-index of 99, his work has been recognized with the Top 100 AI Leaders in Drug Discovery and Advanced Healthcare award. He maintains active collaborations with institutions like Massachusetts General Hospital , Medidata Solutions , and OSF Healthcare . His recent publications reveal a strong focus on: Reinforcement learning applications in medical data analysis Large language model adaptation for clinical tasks Knowledge graph integration with AI systems Synthetic data generation for healthcare Multi-modal learning in clinical contexts Explainable AI for medical applications Dr. Sun's lab ( Sunlab ) emphasizes practical impact over theoretical work, actively collaborating with hospitals and healthtech companies. He welcomes contributions from clinicians, researchers, and industry partners through initiatives like his AI for Health webinar series .
Hang Lu is a Professor and holds the Cecil J. "Pete" Silas Chair of Chemical & Biomolecular Engineering at the Georgia Institute of Technology. Dr. Lu also holds a Love Family Professorship and leads the Lµ Fluidics Group, which focuses on engineering microfluidic systems and machine learning tools to address complex questions in neuroscience, developmental biology, and cell biology that are difficult to address with conventional techniques. Dr. Lu's research lies at the intersection of engineering and biology, with primary interests including: Microfluidic systems for high-throughput screens and image-based genetics and genomics Systems biology: large-scale experimentation and data mining Microtechnologies for optical stimulation and optical recording Big data, machine vision, and automation Developmental neurobiology, behavioral neurobiology, and systems neuroscience Cancer biology, immunology, embryonic development, and stem cells Her laboratory engineers microfluidic devices and BioMEMS to study neuroscience, genetics, cancer biology, and biotechnology. These miniaturized Lab-on-a-chip tools operate at scales comparable to biological systems, leveraging unique micro and nano-scale phenomena to gather large-scale quantitative data about complex biological systems. Current projects include Microfluidics for Life Sciences, Optical Neuron Recordings and Manipulations, Machine Learning Tools for Neuroscience, Measuring and Modeling Behavior, and High-throughput, High-content Cell-based Assays. Analysis of Dr. Lu's recent publications (2024-2025) reveals a strong trend toward integrating microfluidics with advanced computational methods: Development of deep learning frameworks for biological image analysis Advanced neuron tracking and functional imaging techniques Non-invasive characterization of 3D organoid cultures Sophisticated neuromechanical modeling of locomotion Microfluidic temperature control systems for in vivo studies Label-free imaging pipelines for neural development Dr. Lu's significant professional honors include: Cecil J. "Pete" Silas Chair of Chemical & Biomolecular Engineering Love Family Professorship The Lµ Fluidics Group actively mentors students and postdocs, currently accepting new postdoctoral researchers. The lab receives substantial funding for interdisciplinary projects at the engineering-biology interface, with research implications spanning fundamental biological understanding to therapeutic development. The group operates within Georgia Tech's School of Chemical & Biomolecular Engineering, with specialized facilities for microfluidic device fabrication, biological experimentation, and advanced imaging, maintaining strong collaborative ties across engineering, neuroscience, and biological disciplines.
Sriram Subramaniam is a Professor in the Department of Biochemistry and Molecular Biology at the University of British Columbia (UBC) and holds the Gobind Khorana Canada Excellence Research Chair in Precision Cancer Drug Design. His research leverages cryo-electron microscopy (cryo-EM) to advance structural biology and drug design, focusing on protein dynamics and therapeutic target identification. Education: PhD in Physical Chemistry (1987) from Stanford University; MSc in Chemistry (1981) from Indian Institute of Technology, Kanpur. Subramaniam's interdisciplinary work combines cryo-EM with computational tools and molecular biology to study protein structures at atomic resolution. His lab has pioneered cryo-EM applications in precision medicine, including mapping small molecule drugs on patient-specific cancer mutants. Recent publications (2024-2022) highlight his contributions to understanding SARS-CoV-2 immune evasion, structural mechanisms of ATPases, and AI integration in structural biology. His research spans viral entry mechanisms, CRISPR systems, and neurodegenerative disease pathways. Scientific Awards: Gobind Khorana Canada Excellence Research Chair NIH Director’s Award for Scientific Excellence Fellow of the Biophysical Society Breakthrough Prize nomination Based at the Djavad Mowafaghian Center for Brain Health, Subramaniam leads the Program in Cryo-EM Guided Drug Design, contributing to over 177 peer-reviewed publications with a career h-index of 58 and citations exceeding 12,340.
Philip S. Yu is a Distinguished Professor in the Department of Computer Science at the University of Illinois at Chicago and holds the Wexler Chair in Information Technology. Previously, he led the Software Tools and Techniques department at IBM Thomas J. Watson Research Center. Education: B.S. in Electrical Engineering, National Taiwan University M.S. and Ph.D. in Electrical Engineering, Stanford University M.B.A., New York University His research spans data mining , big data , social networks , privacy-preserving data publishing , graph/network mining , recommender systems , and deep learning . He has authored over 970 papers with 74,500+ citations and an H-index of 127. Recent work focuses on heterogeneous graph representation, quantum walks in network analysis, and federated unlearning. Scientific Honors: ACM SIGKDD 2016 Innovation Award IEEE Computer Society 2013 Technical Achievement Award IEEE ICDM 2003 Research Contributions Award IEEE Region 1 Award (1999) UIC Research of the Year (2013) IBM Master Inventor with 300+ patents AI 2000 Most Influential Scholar Honorable Mentions (2024-2025) He served as Editor-in-Chief for ACM Transactions on Knowledge Discovery from Data and IEEE Transactions on Knowledge and Data Engineering , and on steering committees for ACM KDD and IEEE Data Mining. His work bridges theoretical advances in graph neural networks , deep learning , and privacy-preserving systems with applications in healthcare, social media, and enterprise analytics.
Hadi Meidani is a Clinical Associate Professor at the Carle Illinois College of Medicine , specifically within the Department of Biomedical and Translational Sciences at the University of Illinois at Urbana-Champaign . He teaches courses in Civil and Environmental Engineering, including topics like Systems Engineering & Economics , Machine Learning in CEE , and Uncertainty Quantification . Ph.D., Civil Engineering, University of Southern California (2012) M.S., Electrical Engineering, University of Southern California (2012) M.S., Structural Engineering, Sharif University of Technology (2005) B.S., Civil Engineering, K.N. Toosi University of Technology (2002) Dr. Meidani's research focuses on uncertainty quantification , scientific machine learning , and optimization under uncertainty for engineering systems. His work spans stochastic multiscale analysis , physics-informed machine learning , and model reduction techniques. His recent publications emphasize machine learning for infrastructure systems , graph neural networks , physics-informed models , and traffic assignment . Key trends include deep learning , multi-fidelity modeling , and neural operator transformers applied to metamaterial design , seismic reliability , and autonomous freight delivery .
Andrew Holle is an Assistant Professor at the Mechanobiology Institute , National University of Singapore , where he leads the Confinement Mechanobiology Lab within the Department of Biomedical Engineering . His work spans mechanobiology, stem cell differentiation, cancer mechanobiology, and microfluidics, with a focus on understanding how physical confinement influences cellular behavior. Education: B.S.E. in Bioengineering (Minor in Statistics), Arizona State University (2008) Ph.D. in Bioengineering, University of California San Diego (2013) Research in the Confinement Mechanobiology Lab centers on the hypothesis that stem cell differentiation is driven by mechanical cues during migration through confined extracellular matrix (ECM) environments. The lab develops microfluidic systems to mimic ECM confinement and studies its impact on osteogenic differentiation , cancer cell migration , and cellular condensates . Recent publications highlight interdisciplinary approaches combining mechanobiology , nanotechnology , and microfluidics to explore nuclear morphological changes, volume regulation, and ligand signaling in confined cellular environments. Laboratory Members: Privita Edwina (Research Fellow) Vaishnavi Rangaraj (Research Assistant) Sriram Muthukumar (Research Fellow) Chang Ye Ji (PhD Student) Gao Xu (PhD Student) Lim Yuan Bin (PhD Student) Shinny Sunny (PhD Student) Lee Jia Wen Nicole (PhD Student) Li Yixuan (PhD Student)
Vivek Shenoy is the Eduardo D. Glandt President's Distinguished Professor at the University of Pennsylvania, with primary appointments in the Department of Materials Science and Engineering and secondary appointments in Bioengineering and Mechanical Engineering and Applied Mechanics. He leads the Multiscale Mechanobiology and Biomaterials Laboratory, which focuses on developing theoretical frameworks and numerical methods to understand complex biological and engineering systems across multiple length scales. Shenoy's research spans mechanobiology, chromatin organization, cell mechanics, and biomaterials. His work addresses the fundamental challenge of modeling how small-scale cellular phenomena couple with long-range tissue-level interactions across micrometers to centimeters. By integrating insights from soft matter physics, solid mechanics, chemistry, and applied mathematics, his group develops multiphysics continuum and mesoscale theories to elucidate mechanisms controlling both biological and engineering systems. His recent publications demonstrate an increasing focus on nuclear mechanics, chromatin organization, and the interplay between mechanical forces and gene regulation. Analysis of Shenoy's publication record reveals a strong interdisciplinary approach, with high-impact papers spanning biophysics, materials science, and cell biology. His work shows consistent evolution from fundamental mechanics of materials to complex biological systems, with recent emphasis on the mechanical regulation of chromatin architecture, cell migration dynamics in 3D environments, and mechanotransduction in development and disease. His publications appear regularly in top journals including Nature, Science, and their affiliated publications, demonstrating significant influence across multiple fields. Eduardo D. Glandt President's Distinguished Professor Multiple publications in Nature, Science, and PNAS Active research program with publications through 2025 Shenoy actively mentors students and postdocs through his laboratory, with numerous co-authored publications indicating strong mentorship. His research program appears to be well-funded through multiple grants supporting his work in mechanobiology and biomaterials. The Multiscale Mechanobiology and Biomaterials Laboratory maintains active collaborations across disciplines and institutions, reflecting the interdisciplinary nature of his research. The Multiscale Mechanobiology and Biomaterials Laboratory, housed within the Department of Materials Science and Engineering at the University of Pennsylvania, serves as the primary research hub for Shenoy's work. The lab maintains an active presence on social media (Twitter: @ShenoyLab) for updates on activities and publications. Their research approach combines theoretical modeling with experimental validation to address fundamental questions at the interface of mechanics, materials science, and biology.
Melissa Coyle is a Senior Lecturer at the School of Sport, Exercise and Rehabilitation, Marjon University. She specializes in sport and exercise psychology, focusing on applications in sport science, coaching, physical education, outdoor education, and health and well-being. Her qualifications include HCPC registration as a sport and exercise psychologist, BASES chartered scientist, and BASES-accredited sport scientist (Psychology), alongside a PGCert, MSc, and BSc. Her research explores psychological factors in high-stakes environments, including military training, cancer patient exercise programs, and aging populations. Notable studies include a qualitative evaluation of an 8-week exercise referral program for cancer patients and an investigation into psychological factors in Royal Artillery Army Commando training. She has also examined motivations and barriers to indoor bowls participation among over-65s and mental health transitions in university students. Dr. Coyle has been awarded grants for studies like 'Psychological factors in Army Commando training' and 'Exercise adherence for cancer recovery.' Her publications span journals like Psychology of Sport and Exercise and conferences such as the Association of Applied Sport Psychology. She actively contributes to professional bodies like HCPC and BASES. Her teaching emphasizes practical applications of psychology in sports and health, complemented by research-driven insights. Beyond academia, she is an avid golfer and hill walker.
Youngjae You is a Professor of Empire Innovation in the Department of Pharmaceutical Sciences at the University at Buffalo School of Pharmacy. His research focuses on Antibody-Drug Conjugates, Cancer Chemotherapy, Medicinal Chemistry, and Targeted Drug Delivery. He holds adjunct roles at the University of Oklahoma Health Sciences Center and has led numerous grants totaling over $10 million in funding. Key awards include the 2019 Professor of Empire Innovation title and multiple DoD/CDMRP grants. His work emphasizes prodrug design, photodynamic therapy, and combination therapies. Education : PhD in Pharmaceutical Chemistry, Chungnam National University (2001) MS in Pharmaceutical Chemistry, Chungnam National University (2000) BPharm, Chungnam National University (1994) Research Interests : Dr. You specializes in developing light-activatable prodrugs for targeted cancer therapies, including far-red/NIR light-activated delivery systems. His work integrates quantitative pharmacokinetic modeling, singlet oxygen dynamics, and receptor-targeted drug conjugation to enhance therapeutic efficacy while minimizing off-target effects. Key applications include bladder, breast, and ovarian cancers. Funding Highlights : NIH/NIGMS: $1.37M (2023-2027) for light-responsive drug delivery National Cancer Institute: $2.1M (2022-2027) for bladder cancer treatments DoD/CDMRP/PRCRP: $392K (2017-2020) for photodynamic-chemotherapy combinations Awards : PHF Presidential Professorship (2018) American Cancer Society Research Scholar Grant (2013) Multiple DoD/CDMRP Idea Awards Service & Grants : Serves as Principal Investigator on 8 major grants. Active reviewer for Wellcome Trust, NIH, and international funding agencies. Holds patents on BODIPY derivatives and singlet oxygen-labile linkers. Lab & Collaborations : Leads the You Lab at UB, collaborating with bioengineers and clinicians to advance photomedicine and targeted drug delivery systems. Engaged in multidisciplinary teams addressing spatiotemporal control in cancer treatments.
